We aimed to investigate the effects of NAC on PD-L1 (SP142) status and its clinical significance in TNBC. Methods: Paired samples of biopsy and resection specimens were collected from 182 patients with TNBC before and after NAC.

Sep 10, 2021 · We review the diagnostic utility of PD-L1 (by clone SP142) immunohistochemistry in large-cell lymphomas, mainly consisting of classic Hodgkin lymphoma (CHL) and diffuse large B-cell lymphoma (DLBCL). Neoplastic PD-L1 (nPD-L1) expression on Hodgkin and Reed-Sternberg cells is well-established among prototypic CHL.

Jun 16, 2017 · Programmed death-ligand 1 (PD-L1) expression is regarded as a predictive marker for anti-PD-1/PD-L1 therapy. The purpose of study was to explore the changes in PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) during treatment.

Mar 10, 2025 · Our findings uncover a protumoral aspect of STING activation mediated by cell-intrinsic PD-L1 and propose a promising strategy to boost antitumor immunity by fine-tuning STING signaling outputs.

Jan 29, 2019 · EBNA2 induces expression of PD-L1 in lymphoma cells through downregulation of miR-34a [18], which targets PD-L1 [19]. These studies demonstrate that EBV uses PD-L1 to evade immunosurveillance, which might be also the case in EBVaGC, although both LMP-1 and EBNA2 are not expressed in EBVaGC.

Nov 7, 2019 · In this review, we provide current knowledge of PD-L1 regulatory mechanisms at the transcriptional, posttranscriptional, post-translational, and extracellular levels, and discuss the implications of these findings in cancer diagnosis and immunotherapy.

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple im-mune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.

We compared the alterations in PD-L1 expression levels using western blotting, flow cytometry, and quantitative polymerase chain reaction. We also investigated gene expression using RNA sequencing.

Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD‑1)/programmed death ligand 1 (PD‑L1) axis have achieved marked and durable efficacy in patients with different...

PD-1 and PD-L1 are immune checkpoint proteins whose binding ultimately result in T cell exhaustion and self-tolerance. Blocking this pathway 'releases the brakes' on the immune system and allows for attack of tumor cells that express PD-L1.